-
2022 International Cancer Immunotherapy Conference Highlights from Day 2
The second day of the 2022 CRI-ENCI-AACR International Cancer Immunotherapy Conference (CICON22) started off by delving deeper… -
2022 International Cancer Immunotherapy Conference Highlights from Day 1
Back for the first time since the COVID-19 pandemic began, the sixth annual CRI-ENCI-AACR International Cancer Immunotherapy… -
From Autoimmunity to Cancer Cures: How Diabetes May Hold the Key to Improving Immunotherapy, with Dr. Andrea Schietinger
Biologically, cancer and autoimmunity don’t seem to have much in common. In fact, they appear to be… -
Immunotherapy for Rare Cancers: New Horizons and New Hope
Rare cancers are more common than many realize. Collectively, they account for nearly one in four cases… -
ASCO 2022 Recap: Cancer Immunotherapy Updates
Since the first FDA approval in 2011 to treat cancer patients with checkpoint immunotherapy, doctors have sought… -
ASCO 2022 Preview: The Latest Insights from the Front Lines of Cancer Immunotherapy
CRI’s PRINCE Trial featured at ASCO22, along with sessions that highlight the latest clinical advances in checkpoint…
-
The Many Fates of T Cells with CRI Lloyd J. Old STAR Enrico Lugli, PhD
CRI Lloyd J. Old STAR Enrico Lugli, PhD, is deciphering why some T cells have longevity and…
-
AACR 2022 Recap: T Cells Still On Top, But Make Room for Myeloid Cells
At the 2022 AACR annual meeting, CRI scientists highlighted a wide scope of cancer immunology advances, and…
-
Ira Mellman Receives 2022 AACR-CRI Lloyd J. Old Award in Cancer Immunology
Dr. Ira Mellman, a longtime member of the CRI Scientific Advisory Council, received CRI’s highest scientific career…
